Bruin Biometrics said today it raised $9 million in a new round of financing to support its SEM scanner designed to detect early-stage pressure ulcers.

The SEM scanner is a hand-held device that uses non-invasive biosensor technology to measure sub-epidural moisture, which is associated with localized edema in the initial inflammatory phase of pressure ulcer formation.

Funds from the round will go towards accelerating commercialization of its SEM scanner, which was launched in the UK and Ireland after winning CE Mark approval in 2014, the company said.

“Now that we have seen remarkable clinical results from early adopters, we have the financing needed to support initiatives to make the Scanner the standard of care at every hospital and long-term care facility,” CFO Sammy Lai said in a press release.

The company said it is working towards FDA approval for the device, and hopes to make the product available in the U.S. some time this year.

“Fewer patients are developing pressure ulcers in the UK and Ireland when nurses use the Scanner. We are now equipping BBI with the resources to match the demand for the Scanner, which is growing as more people learn about the device’s clinical impact and the consequential cost savings for the health system,” CEO Martin Burns said in a prepared statement.